Charles River Laboratories Long Term Debt 2010-2024 | CRL

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Charles River Laboratories long term debt for 2023 was $2.647B, a 2.23% decline from 2022.
Charles River Laboratories long term debt for 2022 was $2.708B, a 1.65% increase from 2021.
Charles River Laboratories long term debt for 2021 was $2.664B, a 38.04% increase from 2020.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Charles River Laboratories long term debt for 2023 was $2.647B, a 2.23% decline from 2022.
Charles River Laboratories long term debt for 2022 was $2.708B, a 1.65% increase from 2021.
Charles River Laboratories long term debt for 2021 was $2.664B, a 38.04% increase from 2020.

Related Stocks
Company Name	Market Cap
Elevance Health (ELV)	$93.4B
Cencora (COR)	$48.3B
DiDi Global (DIDIY)	$22.2B
Natera (NTRA)	$22.1B
ICON (ICLR)	$17.7B
Viatris (VTRS)	$16B
Avantor (AVTR)	$14.1B
Revvity (RVTY)	$13.6B
CochLear (CHEOY)	$12.8B
Solventum (SOLV)	$12.2B
BioMerieux (BMXMF)	$11.9B
Medpace Holdings (MEDP)	$10.5B
HealthEquity (HQY)	$9.1B
Doximity (DOCS)	$9B
Sonic Healthcare (SKHHY)	$8.9B
Bausch + Lomb (BLCO)	$6.9B
Life Times (LTH)	$5.1B
Organon (OGN)	$3.9B
Sotera Health (SHC)	$3.6B
BrightSpring Health Services (BTSG)	$3.3B
Surgery Partners (SGRY)	$2.9B
Concentras Parent (CON)	$2.8B
PACS (PACS)	$2.5B
Alignment Healthcare (ALHC)	$2.3B
Ardent Health Partners (ARDT)	$2.3B
Premier (PINC)	$2.2B
GeneDx Holdings (WGS)	$2.2B
Ryman Healthcare (RYHTY)	$2B
GoodRx Holdings (GDRX)	$1.9B
Teladoc Health (TDOC)	$1.8B